GoldenGolden
Advanced Search
Sofinnova Partners

Sofinnova Partners

An independent venture capital firm based in Paris that provides funding for seed, early stage and late stage biotechnology ventures

Sofinnova Partners is an independent venture capital firm from Paris, France that provides funding for seed, early stage and late stage ventures. Founded in 1972, the firm has financed and has partnered with almost 500 companies. They invest in companies in the life science sector, especially those that work with biopharmaceuticals, biotech, medical devices, and industrial biotechnology. It usually invests in Round A, and leads its portfolio companies until exit.

The company prioritizes projects with strong intellectual property and whose founders have pharmaceutical or industrial experience. They invest in start-ups usually from the academic world, as well as spin-offs.

Founded in 1974, Sofinnova is a clinical-stage biopharmaceutical investment firm headquartered in Menlo Park, California. The firm seeks to invest in late pre-clinical and clinical therapeutic companies across the United States and Europe.

Sofinnova Ventures partners with entrepreneurs to secure initial funding, help their partner companies build successful teams, find customers, and help them complete acquisitions and IPOs.

Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are business operators with domain and investment experience. Sofinnova knows how to help entrepreneurs build successful, global businesses.

Timeline

July 30, 1972
Founded

Invested in

Associated investment funds

Patents

Products

Funding Rounds Participated In

People

Name
Role
LinkedIn

Lucia Faccio

Partner, Sofinnova Telethon Fund

Alan colowick, MD MPH

Partner

Alex Chan

Accounting Manager

Alex Dulnev

IT Manager

Alfred Yue

Vice President Finance

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Abivax

AblaCare

AFYX Therapeutics

AgroSavfe

Comet Biorefining

News

Title
Author
Date
Publisher
Description
Conor Hale
July 13, 2021
FierceBiotech
Shortly after raising an oversubscribed capital round for clinical-stage companies, Sofinnova Partners is back to announce €63 million ($75 million) for its third acceleration fund aimed at nascent medtech developers.
Mnemo Therapeutics
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mnemo Therapeutics, ein Biotechnologie-Unternehmen, das leistungsstarke Zelltherapien entwickelt, die eine neuartige...
Heather McKenzie
June 16, 2021
BioSpace
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
FinSMEs
June 16, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Mnemo Therapeutics
June 16, 2021
www.prnewswire.com:443
/PRNewswire/ -- Mnemo Therapeutics, a biotechnology company developing powerful cell therapies using a novel target identification engine, stronger T cells and...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.